Abstract
Smoking-related premature mortalities are highly prevalent in those with schizophrenia, and cessation rates from behavioural therapy are low. Pharmacotherapy combined with behavioural treatment appears to be effective in promoting cessation in this population and should be initiated before the patient’s target quit date. As relapses are frequent, treatment should be followed up with maintenance pharmacotherapy in combination with behavioural treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agaku IT, King BA, Dube SR. Current cigarette smoking among adults—United States, 2005–2012. MMWR Morb Mortal Wkly Rep. 2014;63(2):29–34.
Dickerson F, Stallings CR, Origoni AE, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011. Psychiatr Serv. 2013;64(1):44–50.
Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248–54.
Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212–7.
Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183–94.
Cather C, Pachas GN, Cieslak KM, et al. Achieving smoking cessation in individuals with schizophrenia: special considerations. CNS Drugs. 2017;31(6):471–81.
Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–81.
Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341–50.
Mitchell AJ, Vancampfort D, De Hert M, et al. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. Gen Hosp Psychiatry. 2015;37(1):14–23.
Huang Y, Lewis S, Britton J. Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis. BMC Public Health. 2014;14:1024.
Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;2:CD007253.
Evins AE, West R, Russ C, et al. Neuropsychiatric safety and efficacy of varenicline and bupropion vs. nicotine patch and placebo in the psychiatric cohort of the EAGLES trial [abstract]. In: Society for Research on Nicotine and Tobacco, 22nd Annual Meeting; 2016.
Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–20.
Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311(2):193–4.
Kelly DL, Raley HG, Lo S, et al. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophr Bull. 2012;38(3):543–51.
Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64–71.
Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289–94.
Tidey JW, Colby SM, Xavier EM. Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine Tob Res. 2014;16(3):326–34.
Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469–94.
Tidey JW, Cassidy RN, Miller ME. Smoking topography characteristics of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine Tob Res. 2016;18(9):1807–12.
Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73(5):654–60.
Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311(2):145–54.
Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry. 2012;73(1):95–102.
Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218–25.
Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27(4):380–6.
George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835–42.
Funding
The preparation of this review was not supported by any external funding.
Author information
Authors and Affiliations
Consortia
Ethics declarations
Conflict of interest
The article was adapted from Cather et al. [6] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Combine pharmacotherapy with behavioural therapy to help individuals with schizophrenia stop smoking. Drugs Ther Perspect 34, 165–168 (2018). https://doi.org/10.1007/s40267-018-0477-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-018-0477-3